These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34349010)

  • 1. Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study.
    Sullivan KJ; Blackshear C; Simino J; Tin A; Walker KA; Sharrett AR; Younkin S; Gottesman RF; Mielke MM; Knopman D; Windham BG; Griswold ME; Mosley TH
    Neurology; 2021 Sep; 97(11):e1123-e1131. PubMed ID: 34349010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year change in plasma amyloid beta levels and late-life cognitive decline.
    Okereke OI; Xia W; Selkoe DJ; Grodstein F
    Arch Neurol; 2009 Oct; 66(10):1247-53. PubMed ID: 19822780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    Lu Y; Pike JR; Chen J; Walker KA; Sullivan KJ; Thyagarajan B; Mielke MM; Lutsey PL; Knopman D; Gottesman RF; Sharrett AR; Coresh J; Mosley TH; Palta P
    JAMA; 2024 Oct; 332(15):1258-1269. PubMed ID: 39068543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Plasma Aβ
    Johnson EL; Sullivan KJ; Schneider ALC; Simino J; Mosley TH; Kucharska-Newton A; Knopman DS; Gottesman RF
    Neurology; 2023 Sep; 101(13):e1319-e1327. PubMed ID: 37541842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Analysis Identifies Circulating Proteins Associated With Plasma Amyloid-β and Incident Dementia.
    Tin A; Sullivan KJ; Walker KA; Bressler J; Talluri R; Yu B; Simino J; Gudmundsdottir V; Emilsson V; Jennings LL; Launer L; Mei H; Boerwinkle E; Windham BG; Gottesman R; Gudnason V; Coresh J; Fornage M; Mosley TH
    Biol Psychiatry Glob Open Sci; 2023 Jul; 3(3):490-499. PubMed ID: 37519456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis.
    Iulita MF; Ganesh A; Pentz R; Flores Aguilar L; Gubert P; Ducatenzeiler A; Christie S; Wilcock GK; Cuello AC
    J Alzheimers Dis; 2019; 67(1):327-341. PubMed ID: 30636741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study.
    Townsend MK; Okereke OI; Xia W; Yang T; Selkoe DJ; Grodstein F
    Alzheimer Dis Assoc Disord; 2012; 26(1):50-4. PubMed ID: 21502851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
    Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
    Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.
    Devanand DP; Schupf N; Stern Y; Parsey R; Pelton GH; Mehta P; Mayeux R
    Neurology; 2011 Jul; 77(2):125-31. PubMed ID: 21715709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.
    Verberk IMW; Slot RE; Verfaillie SCJ; Heijst H; Prins ND; van Berckel BNM; Scheltens P; Teunissen CE; van der Flier WM
    Ann Neurol; 2018 Nov; 84(5):648-658. PubMed ID: 30196548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study.
    Wang J; Qiao F; Shang S; Li P; Chen C; Dang L; Jiang Y; Huo K; Deng M; Wang J; Qu Q
    J Alzheimers Dis; 2018; 64(1):61-69. PubMed ID: 29865072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.
    Simino J; Wang Z; Bressler J; Chouraki V; Yang Q; Younkin SG; Seshadri S; Fornage M; Boerwinkle E; Mosley TH
    PLoS One; 2017; 12(7):e0180046. PubMed ID: 28704393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.
    Palmqvist S; Janelidze S; Stomrud E; Zetterberg H; Karl J; Zink K; Bittner T; Mattsson N; Eichenlaub U; Blennow K; Hansson O
    JAMA Neurol; 2019 Sep; 76(9):1060-1069. PubMed ID: 31233127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort.
    Gottesman RF; Albert MS; Alonso A; Coker LH; Coresh J; Davis SM; Deal JA; McKhann GM; Mosley TH; Sharrett AR; Schneider ALC; Windham BG; Wruck LM; Knopman DS
    JAMA Neurol; 2017 Oct; 74(10):1246-1254. PubMed ID: 28783817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.
    Regenold WT; Blumenthal JB; Loreck DJ; Mordecai KL; Scarinzi G; Doddi SR; Adler L
    Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):347-352. PubMed ID: 28449585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study.
    Knopman DS; Gottesman RF; Sharrett AR; Tapia AL; DavisThomas S; Windham BG; Coker L; Schneider ALC; Alonso A; Coresh J; Albert MS; Mosley TH
    Alzheimers Dement; 2018 Nov; 14(11):1406-1415. PubMed ID: 29763593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults.
    Peng X; Xu Z; Mo X; Guo Q; Yin J; Xu M; Peng Z; Sun T; Zhou L; Peng X; Xu S; Yang W; Bao W; Shan Z; Li X; Liu L
    Diabetologia; 2020 May; 63(5):954-963. PubMed ID: 32034441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.